urinary%20tract%20infection%20-%20uncomplicated
URINARY TRACT INFECTION - UNCOMPLICATED
Acute uncomplicated urinary tract infection (UTI) is one of the most common bacterial infections in adults that may involve the lower or upper urinary tract or both.
Acute uncomplicated cystitis is an infection limited to the lower urinary tract while acute uncomplicated pyelonephritis is an infection that involves the upper urinary tract (renal parenchyma and pelvicaliceal system) that usually has significant bacteriuria.
Recurrent UTI is characterized by 2 culture-proven episodes of uncomplicated and/or complicated UTI in the last 6 months or ≥3 episodes with positive cultures in the last 12 months in patients with no urinary tract structural or functional abnormalities.

Urinary%20tract%20infection%20-%20uncomplicated Treatment

Principles of Therapy

  • Choice of antibiotic for empirical therapy should be based on spectrum and susceptibility patterns of uropathogens, efficacy, tolerability, adverse effects including ecological effects, availability, and cost
  • No specific antibiotic regimen is recommended for pregnant women since all antibiotics studied were shown to be effective
  • Treatment is not required for asymptomatic bacteriuria in postmenopausal women and management should be as for premenopausal women
  • In postmenopausal women, treatment of acute cystitis and pyelonephritis is the same to that in premenopausal women; however, short-term treatment in cystitis is not well-established

Acute Uncomplicated Pyelonephritis

Choice of Empiric Therapy 

  • Selection of antimicrobial agent will depend on local sensitivity patterns of uropathogens, whether or not the patient is hospitalized, and the relative costs of therapy
    • In cases where local resistance patterns are not known, empirical therapy should include initial intravenous (IV) dose of a long-acting parenteral antimicrobial agent and starting with a broader-spectrum agent and then narrowing the therapy when laboratory results are available
    • Patients with signs of urosepsis should be given empiric antimicrobial therapy with coverage for extended spectrum β-lactamase (ESBL)-producing organisms  
    • Oral therapy should always be considered in patients with mild to moderate symptoms
    • Parenteral therapy should be used in patients who are too ill to take oral antibiotics, then switch to oral therapy once tolerated
  • Patient should be treated for a total of 7-14 days
    • Therapy for >14 days has not shown any benefit and is not recommended except in relapse cases caused by the same pathogen

Pharmacotherapy

Acute Uncomplicated Cystitis

First-line Options 

  • Appropriate agents should have minimal resistance and tendency for ecological adverse effects (eg minimal effect on normal fecal flora)
    • Fosfomycin and Nitrofurantoin should not be used if early pyelonephritis is suspected
  • Fosfomycin (single dose)
    • A phosphonic acid derivative that has activity against both Gram-negative and Gram-positive bacteria
    • Has inferior microbiological efficacy rate but with comparable clinical efficacy rate as compared with standard short-course regimens
    • In vitro studies have shown activity against Vancomycin-resistant enterococci (VRE), Methicillin-resistant S aureus (MRSA), and ESBL-producing Gram-negative rods
  • Nitrofurantoin (for 5-7 days)
    • Antibacterial activity is limited to the urinary tract and is suitable only for the treatment or prophylaxis of uncomplicated UTIs
    • Has low resistance rates and with 88-93% clinical cure rate and 81-92% bacterial cure rate based on studies
      • With similar clinical and microbiological cure rates as with Co-trimoxazole
    • Not to be given during the end of pregnancy
  • Pivmecillinam (for 3-7 days)
    • An extended Gram-negative spectrum penicillin that is used only for the treatment of UTI
    • Has a low risk of selection for resistance and because of its low resistance rates, it is an agent of choice in some European countries
    • Randomized trials showed clinical efficacy is less than the other recommended agents

Alternative Agents  

  • Co-trimoxazole (for 3 days)
    • Remains to be effective in treating patients with acute uncomplicated cystitis and may be considered in areas where resistance rate to E coli is <20%
      • Has early clinical and microbiological cure rates of 90-100%
    • Use is associated with increased resistance but generally does not have a tendency for ecological adverse effects
    • Not to be given in the last trimester of pregnancy
  • Trimethoprim (for 5 days)
    • May be considered in areas where resistance rate to E coli is <20%
    • Not to be given in the first trimester of pregnancy 
  • Cephalosporins and aminopenicillins with or without β-lactamase inhibitors
    • Recommended only in patients with uncomplicated cystitis when other recommended agents cannot be used
    • Have inferior efficacy in managing acute cystitis which is probably due to persistence of the vaginal reservoir for infection; these antimicrobials also cause ecological collateral damage
    • Broad-spectrum cephalosporins have been shown to be associated with ESBL resistance among Gram-negative bacteria
    • Amoxicillin or Ampicillin alone is not recommended to be used for empirical treatment
  • Fluoroquinolones (for 3 days)
    • Recommended to be used only in cases where other agents cannot be used due to the possibility of promoting resistance among uropathogens and other organisms that can cause more serious infections at other sites
      • Increased usage was shown to increase rates of MRSA
    • Remain very effective for the treatment of acute cystitis however has increased resistance rate
    • Overall clinical and microbiological efficacy rates are consistently high
    • Single-dose therapy is available but with possibly lower efficacy rates than with longer regimens

Acute Uncomplicated Pyelonephritis

Fluoroquinolones (for 5-7 days) 

  • Recommended as 1st-line oral therapeutic option in areas with <10% resistance rate to E coli, parenteral in severe cases

Cephalosporins 

  • 3rd generation oral cephalosporins may be used as an alternative agent in patients with mild-moderate pyelonephritis
    • Studies have demonstrated similar clinical efficacy as with Ciprofloxacin
    • An initial parenteral dose of Ceftriaxone is recommended when Cefpodoxime, Ceftibuten or Co-trimoxazole was used empirically
  • Parenteral cephalosporins may be given in hospitalized patients in areas with ESBL-producing E coli resistance rates of <10%
    • An initial parenteral dose of Ceftriaxone is recommended in areas with >10% fluoroquinolone-resistance rate or when Co-trimoxazole or oral β-lactam agents were used empirically
      • Shown to significantly improve the microbiological eradication rate and moderately improve the clinical cure rates in patients with resistance to Co-trimoxazole
      • Combination of Ceftriaxone and Co-trimoxazole was shown to result in improved clinical and bacterial cure rates
      • Ertapenem is an alternative agent for patients with allergy or expected resistance to Ceftriaxone, and aminoglycosides are given to patients who cannot use either agents
  • Ceftolozane/tazobactam and Ceftazidime/avibactam can also be used as empirical parenteral therapies in uncomplicated pyelonephritis 

Aminoglycoside

  • May be considered in areas with fluoroquinolone-resistant and ESBL-producing E coli (>10%)
    • An initial parenteral 24-hour dose of aminoglycoside is recommended in areas with >10% fluoroquinolone resistance rate or when oral β-lactam agents were used empirically

Carbapenem

  • May be considered in areas with >10% rates of fluoroquinolone-resistant and ESBL-producing E coli or in patients with early culture findings of multidrug-resistant organisms

Aminopenicillin with β-lactamase inhibitor

  • Cannot be given as empirical therapy for acute pyelonephritis but can be used after susceptibility testing has shown growth of susceptible Gram-positive organism
  • May be given in hospitalized patients in infections with known susceptible Gram-positive pathogens

Co-trimoxazole (for 14 days) 

  • Cannot be given as empirical therapy due to increasing E coli resistance rates but can be used after sensitivity has been confirmed through susceptibility testing

Other Agents

  • New antimicrobial agents that may be used for the inpatient treatment of uncomplicated pyelonephritis include Cefiderocol, Plazomicin, Imipenem/cilastatin and Meropenem/vaborbactam

Recurrent UTI

Antibiotic Treatment

  • Acute self-treatment using a short-course regimen may be an option in women with clearly documented recurrent infections and compliant with medical instructions who are not suitable for or unwilling to take the long-term daily prophylaxis    
    • Treatment is modified once culture results are available 
  • Depending on local resistance patterns, 1st-line agents usually include Nitrofurantoin, Fosfomycin and Co-trimoxazole which are given in the shortest possible duration, ie <7 days 
  • Antibiotic resistance may be treated with a short course of culture-guided parenteral antibiotics
  • Treatment of asymptomatic bacteriuria in patients with recurrent UTI is not recommended

Prophylaxis

  • Should be given after eradication of UTI has been confirmed through a negative culture obtained 1-2 weeks after treatment
    • Treatment duration is variable (eg 3-6 months to 1 year) and must include periodic monitoring and assessment
  • Continuous low-dose antibiotic and post-coital prophylaxis are given when non-antimicrobial interventions have been unsuccessful 
    • Antibiotics given include Co-trimoxazole, Nitrofurantoin, Trimethoprim, Fosfomycin, or a quinolone (Norfloxacin or Ciprofloxacin); Cefalexin or Cefaclor may be given if pregnant
    • Consider post-coital prophylaxis in pregnant women with a history of frequent UTIs prior to pregnancy
  • Co-trimoxazole and Norfloxacin as prophylactic agents were shown to reduce the recovery rate of aerobic Gram-negative uropathogens
  • Nitrofurantoin intermittently sterilizes the urine and possibly inhibits bacterial attachment causing lower recurrence rate 

Others 

  • Behavioral modifications such as increasing fluid intake, post-coital urination, avoiding occlusive underwear or douching, etc, may help reduce the risk of recurrent UTI
  • Vaginal Estrogen replacement may be advised to peri and postmenopausal women with no contraindications who experience recurrent UTI
    • Has been shown to cause reappearance of vaginal lactobacilli which lowers vaginal pH preventing the overgrowth and colonization of Enterobacteriaceae in the vagina
  • Cranberry products may be helpful
  • Immunoactive prophylaxis (OM-89) can be recommended for women with recurrent UTI 
  • Other promising non-antimicrobial alternatives include probiotic lactobacilli, D-mannose and intravesical hyaluronic acid/chondroitin instillation, though further evidence is needed before these are recommended
    • Acupuncture may be an alternative option in preventing recurrent UTI in women who are unresponsive to or intolerant of antibiotic prophylaxis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.